Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Authors
Keywords
DPP-4 inhibitor, Linagliptin, Neointima formation, VSMC proliferation
Journal
Cardiovascular Diabetology
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-11-21
DOI
10.1186/s12933-014-0154-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
- (2014) Takashi Nomiyama et al. DIABETES
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies
- (2014) Elizabeth M. Round et al. DRUGS & AGING
- Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats
- (2014) Shinji Takai et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Linagliptin: from bench to bedside
- (2014) John Doupis Drug Design Development and Therapy
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
- (2013) Maximilian von Eynatten et al. Cardiovascular Diabetology
- Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial
- (2013) Zhengpei Zeng et al. CURRENT MEDICAL RESEARCH AND OPINION
- Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
- (2013) Nasib Ervinna et al. ENDOCRINOLOGY
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restoring stem cell mobilization to promote vascular repair in diabetes
- (2013) Mattia Albiero et al. VASCULAR PHARMACOLOGY
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
- (2012) Theresa R. Bomfim et al. JOURNAL OF CLINICAL INVESTIGATION
- Dipeptidyl Peptidase-4 Inhibitor
- (2012) Toyoaki Murohara JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
- (2012) Soo Lim et al. PLoS One
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
- (2011) Hiromasa Goto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
- (2011) Takashi Nomiyama et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury
- (2009) Takashi Nomiyama et al. CIRCULATION
- Cardiovascular effects of acute hyperglycaemia: pathophysiological underpinnings
- (2008) Antonio Ceriello Diabetes & Vascular Disease Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started